Analysts Offer Insights on Healthcare Companies: Axovant Sciences (NYSE: AXON), Surgical Care (NASDAQ: SCAI) and Alder Biopharmaceuticals (NASDAQ: ALDR)

By Carrie Williams

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Axovant Sciences (NYSE: AXON), Surgical Care (NASDAQ: SCAI) and Alder Biopharmaceuticals (NASDAQ: ALDR).

Axovant Sciences (NYSE: AXON)

Jefferies analyst Biren Amin reiterated a Buy rating on Axovant Sciences (NYSE: AXON) yesterday and set a price target of $31. The company’s shares closed yesterday at $13.62.

Amin wrote:

“We hosted an investor lunch with Axovant’s mgmt team while at our London Healthcare Conference. There was discussion around how the failure of Lundbeck’s idalopiridine in STARSHINE is not an appropriate comparison for intepirdine’s MINDSET.”

According to TipRanks.com, Amin is a 4-star analyst with an average return of 6.0% and a 54.1% success rate. Amin covers the Healthcare sector, focusing on stocks such as Bellicum Pharmaceuticals, Anthera Pharmaceuticals, and Aquinox Pharmaceuticals.

Currently, the analyst consensus on Axovant Sciences is Moderate Buy and the average price target is $31, representing a 127.6% upside.

In a report issued on November 8, JMP Securities also reiterated a Buy rating on the stock.
Surgical Care (NASDAQ: SCAI)

Jefferies analyst Brian Tanquilut reiterated a Hold rating on Surgical Care (NASDAQ: SCAI) yesterday and set a price target of $49. The company’s shares closed yesterday at $41.97.

Tanquilut said:

“We attribute this relative softness to the toughest volume comp of the year for SCAI. As we look to the next few quarters, investors appear concerned about continued tough comparisons for 4Q16 and 1Q17 of 9% and 10% respectively.”

According to TipRanks.com, Tanquilut is ranked 0 out of 5 stars with an average return of -9.0% and a 38.8% success rate. Tanquilut covers the Healthcare sector, focusing on stocks such as Five Star Quality Care, Quest Diagnostics Inc., and U.S. Physical Therapy.

Surgical Care has an analyst consensus of Moderate Buy.

Alder Biopharmaceuticals (NASDAQ: ALDR)

In a report released yesterday, Brian Abrahams from Jefferies reiterated a Buy rating on Alder Biopharmaceuticals (NASDAQ: ALDR), with a price target of $57. The company’s shares closed yesterday at $29.58.

According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 4.7% and a 56.8% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as DBV Technologies S.A. – American, Achillion Pharmaceuticals, and Protalix Biotherapeutics.

Currently, the analyst consensus on Alder Biopharmaceuticals is Strong Buy and the average price target is $57, representing a 92.7% upside.

In a report issued on November 10, BMO Capital also initiated coverage with a Buy rating on the stock with a $42 price target.